发明名称 |
IN VIVO HALF LIFE INCREASED FUSION PROTEIN OR PEPTIDE MAINTAINED BY SUSTAINED IN VIVO RELEASE, AND METHOD FOR INCREASING IN VIVO HALF-LIFE USING SAME |
摘要 |
<p>The present invention relates to a fusion protein or peptide, the in vivo half-life of which is increased by maintaining in vivo sustained release, and to a method for increasing in vivo half-life using same. A fusion protein or peptide according to the present invention has excellent in vivo stability by bindinga physiologically active protein or physiologically active peptide to an alpha-1 antitrypsin or alpha-1 antitrypsin mutant with one or more amino acids mutated to maintain the in vivo sustained release and to significantly increase the half-life thereof in blood (T1/2) compared to an inherent physiologically active protein or physiologically active peptide. Thus, a fusion protein or peptide according to the present invention can be useful in developing a sustained-release preparation of a protein or peptide drug.</p> |
申请公布号 |
EP2423233(B1) |
申请公布日期 |
2015.03.11 |
申请号 |
EP20100767304 |
申请日期 |
2010.04.22 |
申请人 |
ALTEOGEN, INC |
发明人 |
CHUNG, HYE SHIN;YOO, SEUNG BUM;LEE, SANG MEE |
分类号 |
C07K19/00;C07K14/475;C07K14/81 |
主分类号 |
C07K19/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|